S-1 as a core anticancer fluoropyrimidine agent

Bibliography

• Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A. Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opin Pharmacother 2011;12:517-31
   PubMed Web of Science ®Google Scholar
• Spazzapan S, Crivellari D, Bedard P, Therapeutic management of breast cancer in the elderly. Expert Opin Pharmacother 2011;12:945-60
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Chaudhuri NK, Danneberg P, Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663-6
   PubMed Web of Science ®Google Scholar
• Wilkoff LJ, Wilcox WS, Burdeshaw JA, Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. J Natl Cancer Inst 1967;39:965-75
   PubMed Web of Science ®Google Scholar
• Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep 1964;35:1-111
   PubMedGoogle Scholar
• Lokich JJ, Ahlgren JD, Gullo JJ, A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32
   PubMed Web of Science ®Google Scholar
• Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8
   PubMed Web of Science ®Google Scholar
• Cunningham D, Atkin W, Lenz HJ, Colorectal cancer. Lancet 2010;375:1030-47
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Sasako M, Sano T, Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 2009;12:37-42
   PubMed Web of Science ®Google Scholar
• Nomura T, Murakami R, Toya R, Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010;76:1347-52
   PubMed Web of Science ®Google Scholar
• Murakami Y, Uemura K, Sudo T, Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 2009;250:950-6
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20
   PubMed Web of Science ®Google Scholar
• Li J, Saif MW. Advancements in the management of pancreatic cancer. JOP 2009;10:109-17
   PubMedGoogle Scholar
• Rutman RJ, Cantarow A, Paschkis KE. The catabolism of uracil in vivo and in vitro. J Biol Chem 1954;210:321-9
   PubMed Web of Science ®Google Scholar
• Handschumacher RE, Welch AD. Microbial studies of 6-azauracil, an antagonist of uracil. Cancer Res 1956;16:965-9
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Griesbach L, Montag BJ, Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Res 1958;18:305-17
   PubMed Web of Science ®Google Scholar
• Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer Res 1958;18:318-28
   PubMed Web of Science ®Google Scholar
• Muggia FM, Peters GJ, Landolph JR Jr. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009;8:992-9
   PubMedGoogle Scholar
• Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem 1961;236:3006-13
   PubMed Web of Science ®Google Scholar
• Danneberg PB, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo. Cancer Res 1958;18:329-34
   PubMed Web of Science ®Google Scholar
• Spears CP, Shahinian AH, Moran RG, In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-6
   PubMed Web of Science ®Google Scholar
• Chaudhuri NK, Mukherjee KL, Heidelberger C. Studies on fluoronated pyrimidines. VII-the degradative pathway. Biochem. Pharmacol 1958;1:328-41
   Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-6
   PubMed Web of Science ®Google Scholar
• Martin DS, Stolfi RL, Sawyer RC, High-dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res 1982;42:3964-70
   PubMed Web of Science ®Google Scholar
• Hoskins J, Butler JS. RNA-based 5-fluorouracil toxicity requires the pseudouridylation activity of Cbf5p. Genetics 2008;179:323-30
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil, inc. into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 1984;44:1358-63
   PubMed Web of Science ®Google Scholar
• Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res 1979;39:2406-13
   PubMed Web of Science ®Google Scholar
• Peters GJ, Noordhuis P, Van Kuilenburg AB, Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol 2003;52:1-12
   PubMed Web of Science ®Google Scholar
• Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970;23:155-60
   PubMed Web of Science ®Google Scholar
• Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980;30:871-9
   PubMedGoogle Scholar
• Mansfield PF, Hohn DC, Fornage BD, Complications and failures of subclavian-vein catheterization. N Engl J Med 1994;331:1735-8
   PubMed Web of Science ®Google Scholar
• Agnelli G, Verso M. Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 2006;3:214-22
   PubMedGoogle Scholar
• Maroun J, Asche C, Romeyer F, A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003;21:1039-51
   PubMed Web of Science ®Google Scholar
• Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003;7:1-93
   PubMedGoogle Scholar
• Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15
   PubMed Web of Science ®Google Scholar
• Borner MM, Schoffski P, de Wit R, Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Tabernero J, Gomez-Espana A, Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25:4224-30
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Cox JV, Butts C, Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19:1720-6
   PubMed Web of Science ®Google Scholar
• Ryu MH, Kang YK. ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Rev Anticancer Ther 2009;9:1745-51
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-73
   PubMed Web of Science ®Google Scholar
• Ajani JA, Rodriguez W, Bodoky G, Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-53
   PubMed Web of Science ®Google Scholar
• Muro K, Boku N, Shimada Y, Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-60
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP, Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704
   PubMed Web of Science ®Google Scholar
• Lembersky BC, Wieand HS, Petrelli NJ, Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64
   PubMed Web of Science ®Google Scholar
• Giller SA, Zhuk RA, Lidak MIu. Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities. Article in Russian. Dokl Akad Nauka SSSR 1967;176:332-5
   PubMedGoogle Scholar
• Buroker T, Miller A, Baker L, Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep 1977;61:1579-80
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996;26:395-403
   PubMed Web of Science ®Google Scholar
• Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009;39:2-15
   PubMed Web of Science ®Google Scholar
• Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978;69:763-72
   PubMedGoogle Scholar
• Fujii S, Kitano S, Ikenaka K, Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979;70:209-14
   PubMedGoogle Scholar
• Cook AF, Holman MJ, Kramer MJ, Trown PW. Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 1979;22:1330-5
   PubMed Web of Science ®Google Scholar
• Ishitsuka H, Miwa M, Takemoto K, Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gann 1980;71:112-23
   PubMedGoogle Scholar
• Liu M, Cao D, Russell R, Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 1998;58:5418-24
   PubMed Web of Science ®Google Scholar
• Temmink OH, de Bruin M, Turksma AW, Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int J Biochem Cell Biol 2007;39:565-75
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81
   PubMed Web of Science ®Google Scholar
• Shimma N, Umeda I, Arasaki M, The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg. Med Chem 2000;8:1697-706
   PubMed Web of Science ®Google Scholar
• Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 2011;10:159-69
   PubMed Web of Science ®Google Scholar
• Reigner B, Watanabe T, Schuller J, Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003;52:193-201
   PubMed Web of Science ®Google Scholar
• Hattori K, Kohchi Y, Oikawa N, Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine. Bioorg Med Chem Lett 2003;13:867-72
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-55
   PubMedGoogle Scholar
• Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9
   PubMed Web of Science ®Google Scholar
• Granat P, Creasey WA, Calabresi P, Handschumacher RE. Investigations with 5-azaorotic acid, an inhibitor of the biosynthesis of pyrimidines de novo. Clin Pharmacol Ther 1965;6:436-47
   PubMed Web of Science ®Google Scholar
• Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 2009;18(3):335-48
   PubMed Web of Science ®Google Scholar
• Hirata K, Horikoshi N, Aiba K, Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-5
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008;14:8-13
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ueda Y, Fuji N, Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol 2006;58:183-8
   PubMed Web of Science ®Google Scholar
• Saif MW, von Borstel R. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol 2006;58:136-42
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S, Fukuda H, Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-9
   PubMed Web of Science ®Google Scholar
• Narahara H, Iishi H, Imamura H, Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011;14:72-80
   PubMed Web of Science ®Google Scholar
• Strumberg D, Bergmann L, Graeven U, First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group). Int J Clin Pharmacol Ther 2010;48:470-2
   PubMed Web of Science ®Google Scholar
• Chu QS, Hammond LA, Schwartz G, Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004;10:4913-21
   PubMed Web of Science ®Google Scholar
• Hoff PM, Saad ED, Ajani JA, Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003;9:134-42
   PubMed Web of Science ®Google Scholar
• van Groeningen CJ, Peters GJ, Schornagel JH, Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18:2772-9
   PubMed Web of Science ®Google Scholar
• Chuah B, Goh BC, Lee SC, Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011;102:478-83
   PubMed Web of Science ®Google Scholar
• Peters GJ, Noordhuis P, Van Groeningen CJ, The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 2004;10:4072-6
   PubMed Web of Science ®Google Scholar
• Scheulen ME, Saito K, Hilger RA, Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lipkin M, Sherlock P, Bell B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology 1963;45:721-9
   PubMed Web of Science ®Google Scholar
• Clarkson B, Ota K, Ohkita T, Kinetics of proliferation of cancer cells in neoplastic effusions in man. Cancer 1965;18:1189-213
   PubMed Web of Science ®Google Scholar
• Terashima M, Irinoda T, Kawamura H, Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale. Cancer Chemother Pharmacol 2003;51:240-6
   PubMed Web of Science ®Google Scholar
• Arai W, Hosoya Y, Hyodo M, Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol 2004;9:143-8
   PubMedGoogle Scholar
• Arai W, Hosoya Y, Haruta H, Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. Int J Clin Oncol 2008;13:515-20
   PubMed Web of Science ®Google Scholar
• Sakuma K, Hosoya Y, Arai W, Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. Int J Clin Oncol 2010;15:166-71
   PubMed Web of Science ®Google Scholar
• Hirose T, Fujita K, Nishimura K, Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol Rep 2010;24:529-36
   PubMed Web of Science ®Google Scholar
• Kim KP, Jang G, Hong YS, Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011;104:605-12
   PubMed Web of Science ®Google Scholar
• Tsunoda A, Nakao K, Watanabe M, Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol 2011;22:355-61
   PubMed Web of Science ®Google Scholar
• Mattison LK, Fourie J, Desmond RA, Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Meijer J, Mul AN, Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010;128:529-38
   PubMed Web of Science ®Google Scholar